HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe. / Amele, Sarah; Sandri, Anastasia Karachalia; Rodger, Alison; Vandekerckhove, Linos; Benfield, Thomas; Milinkovic, Ana; Duvivier, Claudine; Stellbrink, Hans-Jürgen; Sambatakou, Helen; Chkhartishvili, Nikoloz; Caldeira, Luis; Laguno, Monserrat; Domingo, Pere; Wandeler, Gilles; Gisinger, Martin; Kuzovatova, Elena; Dragovic, Gordana; Knysz, Brygida; Matulionyte, Raimonda; Rockstroh, Jürgen Kurt; Lundgren, Jens; Mocroft, Amanda; Peters, Lars; Kronborg, G.; Benfield, T.; Gerstoft, J.; The EuroSIDA Study Group.
In: HIV Medicine, Vol. 23, No. 6, 2022, p. 684-692.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe
AU - Amele, Sarah
AU - Sandri, Anastasia Karachalia
AU - Rodger, Alison
AU - Vandekerckhove, Linos
AU - Benfield, Thomas
AU - Milinkovic, Ana
AU - Duvivier, Claudine
AU - Stellbrink, Hans-Jürgen
AU - Sambatakou, Helen
AU - Chkhartishvili, Nikoloz
AU - Caldeira, Luis
AU - Laguno, Monserrat
AU - Domingo, Pere
AU - Wandeler, Gilles
AU - Gisinger, Martin
AU - Kuzovatova, Elena
AU - Dragovic, Gordana
AU - Knysz, Brygida
AU - Matulionyte, Raimonda
AU - Rockstroh, Jürgen Kurt
AU - Lundgren, Jens
AU - Mocroft, Amanda
AU - Peters, Lars
AU - Kronborg, G.
AU - Benfield, T.
AU - Gerstoft, J.
AU - The EuroSIDA Study Group
N1 - Publisher Copyright: © 2021 British HIV Association.
PY - 2022
Y1 - 2022
N2 - Objectives: Although direct-acting antivirals (DAAs) can clear HCV in nearly all HIV/HCV-coinfected individuals, high rates of reinfection may hamper efforts to eliminate HCV in this population. We investigated reinfection after sustained virological response (SVR) in HIV/HCV-coinfected individuals in Europe. Methods: Factors associated with odds of reinfection by 2 years after SVR in EuroSIDA participants with one or more HCV-RNA test and 2 years follow-up were assessed using logistic regression. Results: Overall, 1022 individuals were included. The median age was 50 (interquartile range: 43–54 years), and most were male (78%), injection drug users (52%), and received interferon (IFN)-free DAAs (62%). By 24 months, 75 [7.3%, 95% confidence interval (CI): 5.7–8.9%] individuals were reinfected. Among individuals treated prior to 2014, 16.1% were reinfected compared with 4.2% and 8.3%, respectively, among those treated during or after 2014 with IFN-free and IFN-based therapy. After adjustment, individuals who had started treatment during or after 2014 with IFN-free or IFN-based therapy had significantly lower odds of reinfection (adjusted odds ratio = 0.21, 95% CI: 0.11–0.38; 0.43, 95% CI: 0.22–0.83) compared with those who had received therapy before 2014. There were no significant differences in odds of reinfection according to age, gender, European region, HIV transmission risk group or liver fibrosis. Conclusions: Among HIV/HCV-coinfected individuals in Europe, 7.3% were reinfected with HCV within 24 months of achieving SVR, with evidence suggesting that this is decreasing over time and with use of newer HCV regimens. Harm reduction to reduce reinfection and surveillance to detect early reinfection with an offer of treatment are essential to eliminate HCV.
AB - Objectives: Although direct-acting antivirals (DAAs) can clear HCV in nearly all HIV/HCV-coinfected individuals, high rates of reinfection may hamper efforts to eliminate HCV in this population. We investigated reinfection after sustained virological response (SVR) in HIV/HCV-coinfected individuals in Europe. Methods: Factors associated with odds of reinfection by 2 years after SVR in EuroSIDA participants with one or more HCV-RNA test and 2 years follow-up were assessed using logistic regression. Results: Overall, 1022 individuals were included. The median age was 50 (interquartile range: 43–54 years), and most were male (78%), injection drug users (52%), and received interferon (IFN)-free DAAs (62%). By 24 months, 75 [7.3%, 95% confidence interval (CI): 5.7–8.9%] individuals were reinfected. Among individuals treated prior to 2014, 16.1% were reinfected compared with 4.2% and 8.3%, respectively, among those treated during or after 2014 with IFN-free and IFN-based therapy. After adjustment, individuals who had started treatment during or after 2014 with IFN-free or IFN-based therapy had significantly lower odds of reinfection (adjusted odds ratio = 0.21, 95% CI: 0.11–0.38; 0.43, 95% CI: 0.22–0.83) compared with those who had received therapy before 2014. There were no significant differences in odds of reinfection according to age, gender, European region, HIV transmission risk group or liver fibrosis. Conclusions: Among HIV/HCV-coinfected individuals in Europe, 7.3% were reinfected with HCV within 24 months of achieving SVR, with evidence suggesting that this is decreasing over time and with use of newer HCV regimens. Harm reduction to reduce reinfection and surveillance to detect early reinfection with an offer of treatment are essential to eliminate HCV.
KW - direct-acting antivirals
KW - HCV
KW - HIV
KW - interferon
KW - reinfection
U2 - 10.1111/hiv.13212
DO - 10.1111/hiv.13212
M3 - Journal article
C2 - 34882940
AN - SCOPUS:85120978428
VL - 23
SP - 684
EP - 692
JO - HIV Medicine
JF - HIV Medicine
SN - 1464-2662
IS - 6
ER -
ID: 329429340